Your browser doesn't support javascript.
loading
Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency.
Sefer, Asena Pinar; Abolhassani, Hassan; Ober, Franziska; Kayaoglu, Basak; Bilgic Eltan, Sevgi; Kara, Altan; Erman, Baran; Surucu Yilmaz, Naz; Aydogmus, Cigdem; Aydemir, Sezin; Charbonnier, Louis-Marie; Kolukisa, Burcu; Azizi, Gholamreza; Delavari, Samaneh; Momen, Tooba; Aliyeva, Simuzar; Kendir Demirkol, Yasemin; Tekin, Saban; Kiykim, Ayca; Baser, Omer Faruk; Cokugras, Haluk; Gursel, Mayda; Karakoc-Aydiner, Elif; Ozen, Ahmet; Krappmann, Daniel; Chatila, Talal A; Rezaei, Nima; Baris, Safa.
Afiliación
  • Sefer AP; Division of Pediatric Allergy/Immunology, Marmara University, Istanbul, Turkey.
  • Abolhassani H; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Ober F; Marmara University, The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Kayaoglu B; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Bilgic Eltan S; Division of Clinical Immunology, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden.
  • Kara A; Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Erman B; Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
  • Surucu Yilmaz N; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
  • Aydogmus C; Division of Pediatric Allergy/Immunology, Marmara University, Istanbul, Turkey.
  • Aydemir S; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Charbonnier LM; Marmara University, The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Kolukisa B; TUBITAK Marmara Research Center, Gene Engineering and Biotechnology Institute, Gebze, Turkey.
  • Azizi G; Institute of Child Health, Hacettepe University, Ankara, Turkey.
  • Delavari S; Can Sucak Research Laboratory for Translational Immunology, Center for Genomics and Rare Diseases, Hacettepe University, Ankara, Turkey.
  • Momen T; Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
  • Aliyeva S; Division of Pediatric Allergy and Immunology, University of Health Sciences, Basaksehir Cam Sakura City Hospital, Istanbul, Turkey.
  • Kendir Demirkol Y; Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Tekin S; Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Division of Immunology, Boston, MA, USA.
  • Kiykim A; Division of Pediatric Allergy/Immunology, Marmara University, Istanbul, Turkey.
  • Baser OF; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Cokugras H; Marmara University, The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Gursel M; Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
  • Karakoc-Aydiner E; Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ozen A; Department of Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Krappmann D; Faculty of Medicine, Department of Pediatrics, Marmara University, Istanbul, Turkey.
  • Chatila TA; Division of Pediatric Genetics, University of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey.
  • Rezaei N; Hamidiye Faculty of Medicine, Department of Basic Medical Sciences, Division of Medical Biology, University of Health Sciences, Istanbul, Turkey.
  • Baris S; Faculty of Medicine, Pediatric Allergy and Immunology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
J Clin Immunol ; 42(3): 634-652, 2022 04.
Article en En | MEDLINE | ID: mdl-35079916
ABSTRACT

PURPOSE:

MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency.

METHODS:

The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset analyses, cytokine secretion, and proliferation assays were performed. We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation.

RESULTS:

The mean age of patients and disease onset were 33 ± 17 and 1.6 ± 0.7 months, respectively. The main clinical findings of the disease were recurrent infections (100%), skin involvement (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%). Eosinophilia and high IgE were observed in six (67%) and two (22%) patients, respectively. The majority of patients had normal T and NK cells, while eight (89%) exhibited reduced B cells. Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections. Analyzing this cohort with reported patients revealed overall survival in 58% (11/19), which was higher in patients who underwent HSCT (P = 0.03).

CONCLUSION:

This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Insuficiencia de Crecimiento Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Insuficiencia de Crecimiento Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Turquía